Genocea Biosciences

Latest Headlines

Latest Headlines

Genocea puts pneumococcal vaccine on back burner following PhII failure

On the heels of successful Phase II data for its genital herpes candidate, Genocea reported that its pneumococcal vaccine missed the mark in Phase II.

Genocea halts its antibiotic vaccine program after a Phase II failure

Genocea Biosciences' vaccine for pneumococcal infection missed its goals in a Phase IIa trial, leading the company to pause development and shift its attention to a more promising effort in genital herpes.

Genocea's genital herpes vaccine succeeds in PhII

There is no cure for genital herpes, but Genocea is getting closer to marketing an immunotherapy that could control herpes symptoms. The Massachusetts-based company announced Wednesday that it met its goals in a Phase II study of its investigational GEN-003 vaccine.

Genocea's herpes vaccine hits the mark in Phase II

Genocea Biosciences' in-development vaccine for genital herpes met its goals in a Phase II trial, sending the biotech's shares soaring.

UPDATED: Analyst: Genocea's genital herpes vaccine better positioned than Agenus' to enter market

Genocea Biosciences' GEN-003 vaccine is well-positioned to compete in the genital herpes treatment market. It's in a better position, in fact, than Agenus' HerpV, according to a GlobalData analyst.

Biotechs angling for T-cell response in race for next-gen herpes vaccine

When Australian biotech Admedus announced Phase I results for its herpes simplex virus vaccine last week, it was far from the first company to do so. A whole new generation of vaccinemakers are trying their hand in a race that's heating up.

Biotech's breathless quarter of IPOs brings in $2.1B for R&D;

Back in January, at the annual J.P. Morgan Healthcare Conference, across hotel lobbies and crowded hallways and standing-room-only cafes, one could hardly escape talk about the biotech IPO boom.

Circassia to test U.K. investors' appetite for risk with a $285M IPO

European financial markets have largely missed out on the biotech IPO boom, with the few local companies to go public traveling to the U.S. to file their papers. Now British vaccine developer Circassia is to test investor appetite in the United Kingdom with a bumper $285 million IPO.

Genocea files IPO papers in a bid to raise $75M for vaccine development

The past year will go down as the biggest for biotech IPOs since 2000 and a good time for the firms who braved frosty conditions to go public in 2011 and 2012. Vaccine developer Genocea Biosciences is now set to be among the first to test conditions in 2014 having filed its S-1 just before the holiday season.

Genocea pitches $75M IPO to back T-cell vaccine pipeline work

Genocea Biosciences is throwing its hat in the growing IPO ring. The biotech has laid out plans to raise $75 million to help fund its work on a pair of early-stage T-cell vaccines aimed at herpes and all strains of the bacteria pneumococcus.